Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.62 |
| ▸ | DRD3 | P35462 | 5/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136998 | 1.00 | DRD2 (0.62) | DRD2DRD3DRD4ABCB1MTNR1A | |
| SCHEMBL13137000 | 0.94 | DRD2 (0.53) | DRD2DRD3DRD4ABCB1MTNR1A | |
| Hydrochloric Acid SCHEMBL3051483 | 0.92 | DRD2 (0.61) | DRD2DRD3DRD4ABCB1MTNR1A | |
| Hydrochloric Acid SCHEMBL3039981 | 0.92 | DRD2 (0.61) | DRD2DRD3DRD4ABCB1MTNR1A | |
| Hydrochloric Acid SCHEMBL3039983 | 0.92 | DRD2 (0.61) | DRD2DRD3DRD4ABCB1MTNR1A | |
| SCHEMBL13136995 | 0.92 | DRD2 (0.49) | DRD2DRD3DRD4ABCB1 | |
| Hydrochloric Acid SCHEMBL3047492 | 0.85 | DRD2 (0.52) | DRD2DRD3DRD4ABCB1MTNR1A | |
| Hydrochloric Acid SCHEMBL3047495 | 0.85 | DRD2 (0.52) | DRD2DRD3DRD4ABCB1MTNR1A | |
| SCHEMBL13136993 | 0.85 | ABCB1 (0.57) | ABCB1 | |
| SCHEMBL13136969 | 0.81 | QPCT (0.47) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | DRD2 140/4885DRD3 234/4885DRD4 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.